At NEBULA, we revolutionize drug discovery by providing a comprehensive, physics-based dataset-free genAI solution for mapping the full range of therapeutic target conformations. Unlike traditional drug development focused on small molecule screening, our innovative approach delves deep into the dynamic nature of macromolecular targets—proteins, mRNA, antigens—unveiling their multitude of physiological conformations. Our dataset-free technology integrates generative genAI with molecular dynamics, rooted in physical principles, to generate an exhaustive profile of potential target structures without relying on pre-existing data. By enhancing the understanding of drug targets, we empower pharmaceutical and biotech companies to identify more effective therapeutic molecules, reducing the high failure rates associated with current computational predictions. As a partnership-focused company, NEBULA collaborates closely with pharma and biotech firms, offering customized services. Join us in transforming the drug discovery landscape by unlocking the full potential of therapeutic targets through cutting-edge dataset-free genAI
| Website | https://nebulabio.tech/ |
| Employees | 5 (4 on RocketReach) |
| Founded | 2024 |
| Industry | Biotechnology Research |
| Keywords | Drug Discovery, Generative Ai, Physics Based Modeling, Molecular Modeling, Genai, Precision Medicine, Computational Drug Discovery, Biotechnology, Pharmaceutical, Deep Learning, Machine Learning, Drug Development, Target Identification, Molecular Dynamics, Small Molecule |
| Competitors | Thermo Fisher Scientific, Agilent Technologies, Illumina, Bio-Rad Laboratories, QIAGEN, 10x Genomics, Oxford Nanopore Technologies, PacBio, Zymo Research Corp, Sengenics +45 more (view full list) |
Looking for a particular NEBULA employee's phone or email?
Daniel Wiczew is the Co-Founder and CTO of NEBULA.
4 people are employed at NEBULA.
NEBULA is based in Nancy, Grand Est.